2025: Conference
148-150
2025-05-03
Open Access
IMPLEMENTATION OF TARGET THERAPY IN RELAPSED CLASSIC HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
Received: 2025-05-18
Published: 2025-05-03
Share This Article
How to Cite This Article
IMPLEMENTATION OF TARGET THERAPY IN RELAPSED CLASSIC HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE. (2025). Herald of the National Children’s Medical Center, 148-150. https://hnchmc.uz/jour/article/view/186
Export Citation
For reference managers (Mendeley, Zotero, EndNote)
Abstract
Classic Hodgkin lymphoma (cHL) accounts for approximately 5-6% of childhood malignancies and is one of the most curable cancers in children. While the disease can be cured with limited resources, relapsed or refractory (RR) cHL remains a challenge for up to 15% of patients. Fortunately, Brentuximab vedotin (BV) and anti-PD-1 blocking antibodies, such as nivolumab and pembrolizumab, have proven to be highly effective treatments for cHL and have revolutionized disease management.
List of references
About the Authors
Sayitov B.Sh.
National Children's Medical Center
Iskandarov K.Z.
National Children's Medical Center
Boqiyev S.S.
National Children's Medical Center
Islomov S.T.
National Children's Medical Center
Parpiyev B.U.
National Children's Medical Center
Abdugaffarov A.F.
National Children's Medical Center
How to Cite
IMPLEMENTATION OF TARGET THERAPY IN RELAPSED CLASSIC HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE. (2025). Herald of the National Children’s Medical Center, 148-150. https://hnchmc.uz/jour/article/view/186